1998 Fiscal Year Final Research Report Summary
Basic research for cancer-specific immunotherapy using T cell receptor
| Project/Area Number |
08671369
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | HIROSHIMA UNIVERSITY |
|---|
Principal Investigator |
YAMAGUCHI Oshiyuki Research Institute for Radiation Biology and Medicine, HIROSHIMA UNIVERSITY Assistant professor, 原爆放射能医学研究所, 講師 (10230377)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYAHARA Eiji Hiroshima University Medical Hospital, Medical stuff, 医学部・附属病院, 医員
|
|---|
| Project Period (FY) |
1996 – 1998
|
| Keywords | CTL / T cell receptor (TCR) / malignant effusion |
|---|
| Research Abstract |
Locoregional lymphocytes in the ascites caused from colon cancer were isolated and expanded with interleukin (IL)-2 to be potent effector cells against autologous tumor cells. They were CD4 and Fas-L positive, and produced TNF and IFN-gamma. Their cytotoxicity against autologous tumor cells was abrogated with anti-TCR V beta 20 as well as anti-TCR a alpha beta antibody. This TCR V beta 20 gene was cloned and the CDR3 sequence was identified. Molecular diagnosis for locoregional lymphocytes from cancer patients by PCR using the CDR3 sequence as a primer revealed that 3 of 4 patients with positive response to immunotherapy showed positive bands and 3 of 3 patients with negative response did negative ones. These evidences indicates the possibilities of cancer-specific immunotherapy using the TCR V beta 20 and molecular diagnosis for responder patients against cancer-specific immunotherapy.
|
